5 Micro-Cap Stocks To Buy According To Cathie Wood

Page 5 of 5

1. Compugen Ltd. (NASDAQ:CGEN)

Percentage of ARK Investment Management’s 13F Portfolio: 0.13%

ARK Investment Management’s Stake Value: $32.9 million

Number of Hedge Fund Holders: 13

Market Capitalization: $182.37 million

Established as a computational drug discovery service provider in 1993, Compugen Ltd. (NASDAQ:CGEN) is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel. It accounted for 0.13% of the ARK Investment Management’s portfolio as of the end of the March 2022 quarter, with over 9.8 million shares worth $58.7 million.

SVB Leerink analyst Daina Graybosch lowered the price target on Compugen Ltd. (NASDAQ:CGEN) to $9 from $16 and maintained an Outperform rating on the shares while updating her 2022 outlook.

There were 13 hedge funds that held a position in Compugen Ltd. (NASDAQ:CGEN) worth $44.6 million at the end of the first quarter, the same as the previous quarter worth $55.2 million. Among the hedge funds tracked by Insider Monkey, Jim Simons’ Renaissance Technologies is one of the leading shareholders of Compugen Ltd. (NASDAQ:CGEN), with 9.2 million shares worth close to $40 million.

You can also take a look at 10 Defensive Stocks in Billionaire Ray Dalio’s Latest Portfolio and Michael Burry is Buying These 10 Stocks As Recession Fears Mount

Page 5 of 5